Cluster headache, apart from its legendary reputation as the most violent headache that can exist, suffers from an average 60-month delay in diagnosis. The simplicity of the clinical manifestations, although dramatic, makes this delay inexplicable. The education of emergency department physicians and various specialists not specifically dedicated to headaches allows cluster headache to remain in a lurking position with flourishing periods of disease that are often unpredictable in both onset and disappearance. Older drugs have always shown high efficacy but also an equally high rate of adverse events, often discouraging their appropriate use. The availability of a new drug class such as monoclonal antibodies for calcitonin gene-related peptide or its receptor (CGRP(r)), which have already been efficient for migraine, shows a jeopardized geography of access in the world, and this favors the progression of the episodic form into chronic and of the chronic into refractory.

Cluster Headache is Still Lurking in the Shadows / Martelletti, P.; Curto, M.. - In: PAIN AND THERAPY. - ISSN 2193-8237. - (2021). [10.1007/s40122-021-00278-5]

Cluster Headache is Still Lurking in the Shadows

Martelletti P.
Primo
;
Curto M.
2021

Abstract

Cluster headache, apart from its legendary reputation as the most violent headache that can exist, suffers from an average 60-month delay in diagnosis. The simplicity of the clinical manifestations, although dramatic, makes this delay inexplicable. The education of emergency department physicians and various specialists not specifically dedicated to headaches allows cluster headache to remain in a lurking position with flourishing periods of disease that are often unpredictable in both onset and disappearance. Older drugs have always shown high efficacy but also an equally high rate of adverse events, often discouraging their appropriate use. The availability of a new drug class such as monoclonal antibodies for calcitonin gene-related peptide or its receptor (CGRP(r)), which have already been efficient for migraine, shows a jeopardized geography of access in the world, and this favors the progression of the episodic form into chronic and of the chronic into refractory.
2021
Calcitonin gene-related peptide; Cluster headache; Education; Galcanezumab; Refractory chronic cluster headache; Verapamil
01 Pubblicazione su rivista::01a Articolo in rivista
Cluster Headache is Still Lurking in the Shadows / Martelletti, P.; Curto, M.. - In: PAIN AND THERAPY. - ISSN 2193-8237. - (2021). [10.1007/s40122-021-00278-5]
File allegati a questo prodotto
File Dimensione Formato  
Martelletti_Cluster Headache_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 187.24 kB
Formato Adobe PDF
187.24 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1579076
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 7
social impact